BR112015004629A2 - polipeptídeos de clostridium difficile como vacinas - Google Patents

polipeptídeos de clostridium difficile como vacinas

Info

Publication number
BR112015004629A2
BR112015004629A2 BR112015004629A BR112015004629A BR112015004629A2 BR 112015004629 A2 BR112015004629 A2 BR 112015004629A2 BR 112015004629 A BR112015004629 A BR 112015004629A BR 112015004629 A BR112015004629 A BR 112015004629A BR 112015004629 A2 BR112015004629 A2 BR 112015004629A2
Authority
BR
Brazil
Prior art keywords
vaccines
clostridium difficile
polypeptides
difficile polypeptides
difficile
Prior art date
Application number
BR112015004629A
Other languages
English (en)
Portuguese (pt)
Inventor
Galeotti Cesira
Martinelli Manuele
Scarselli Maria
Pizza Mariagrazia
Unnikrishnan Meera
Leuzzi Rosanna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015004629A2 publication Critical patent/BR112015004629A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015004629A 2012-09-19 2013-09-19 polipeptídeos de clostridium difficile como vacinas BR112015004629A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
BR112015004629A2 true BR112015004629A2 (pt) 2017-11-21

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004629A BR112015004629A2 (pt) 2012-09-19 2013-09-19 polipeptídeos de clostridium difficile como vacinas

Country Status (13)

Country Link
US (1) US9932374B2 (https=)
EP (1) EP2897637A1 (https=)
JP (1) JP2015529677A (https=)
KR (1) KR20150056540A (https=)
CN (1) CN104582722A (https=)
AU (1) AU2013319821A1 (https=)
BR (1) BR112015004629A2 (https=)
CA (1) CA2882620A1 (https=)
IL (1) IL237172A0 (https=)
MX (1) MX2015002485A (https=)
RU (1) RU2015106916A (https=)
SG (1) SG11201500980WA (https=)
WO (1) WO2014045226A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US12076352B2 (en) 2018-06-19 2024-09-03 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
CA2404260A1 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
EP1292686A1 (en) * 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
CA2693958A1 (en) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
BRPI0906060A2 (pt) * 2008-02-28 2015-12-01 3M Innovative Properties Co anticorpos isolados, métodos de preparo de um anticorpo anti-clostridium difficile, composição e método para a detecção da presença de um esporo de clostridium difficile em uma amostra
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
WO2011068953A2 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine

Also Published As

Publication number Publication date
US20150315248A1 (en) 2015-11-05
RU2015106916A (ru) 2016-11-10
IL237172A0 (en) 2015-04-30
CA2882620A1 (en) 2014-03-27
MX2015002485A (es) 2015-06-05
CN104582722A (zh) 2015-04-29
AU2013319821A1 (en) 2015-02-26
SG11201500980WA (en) 2015-04-29
WO2014045226A1 (en) 2014-03-27
KR20150056540A (ko) 2015-05-26
EP2897637A1 (en) 2015-07-29
JP2015529677A (ja) 2015-10-08
US9932374B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
PT4023755T (pt) Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
BR112015000626A2 (pt) processos para preparação de óxido de titânio e outros produtos variados
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2019008359A (es) Cadena j modificada.
MX384212B (es) Metodos para cosechar cultivos de celulas de mamifero.
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
EP3236772A4 (en) Methods of purifying recombinant proteins
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
DK3143138T3 (da) Betinget aktive biologiske proteiner
EP2900697A4 (en) PEPTIDATED PROTEIN KNOCKDOWN
IN2014DN05885A (https=)
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
GT201800102A (es) Polipéptidos que inhiben cd4ol
IL251571A0 (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
IL250646A0 (en) A process for conjugating a peptide or protein with a reagent containing a leaving group that includes a peg moiety
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
LT3191514T (lt) Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą
MX378905B (es) Pestivirus.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.